Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Key Stats

• Today's Range: $0.39 to $0.39
• 50-Day Range: $0.37 to $0.42
• 52-Week Range: $0.23 to $2.83
• Volume: N/A
• Average Volume: 943,490 shs
• Market Capitalization: $26.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Applied Genetic Technologies Stock Analysis - MarketRank™

Applied Genetic Technologies scored higher than 2% of companies evaluated by MarketBeat, and ranked 933rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Applied Genetic Technologies.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Applied Genetic Technologies are expected to decrease in the coming year, from ($0.65) to ($0.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied Genetic Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied Genetic Technologies is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Applied Genetic Technologies has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AGTC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied Genetic Technologies does not currently pay a dividend.

Dividend Growth

Applied Genetic Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -0.62

Short Interest

There is no current short interest data available for AGTC.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for AGTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Applied Genetic Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Applied Genetic Technologies is held by insiders.

Percentage Held by Institutions

Only 22.05% of the stock of Applied Genetic Technologies is held by institutions.

AGTC Stock Analysis - Frequently Asked Questions

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.05.
Read the conference call transcript.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Genetic Technologies investors own include Tesla (TSLA), Meta Platforms (META), NIO (NIO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 8/14/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AGTC
• CIK: 1273636
• Web: www.agtc.com
• Phone: (386) 462-2204
• Fax: N/A
• Employees: 83
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.94 million
• Net Margins: N/A
• Pretax Margin: -21,537.54%
• Return on Equity: -192.90%
• Return on Assets: -92.54%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 1.40
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $320 thousand
• Price / Sales: 83.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.26 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 67,632,000
• Free Float: 64,859,000
• Market Cap: $26.62 million
• Optionable: Optionable
• Beta: 1.55